Discipline and Rules-Based Execution in BHVN Response
This article analyzes Biohaven Ltd. (NASDAQ: BHVN) using AI models to suggest trading strategies. It highlights strong near to mid-term sentiment but a weak long-term outlook, identifying compelling upside potential due to a lack of resistance levels above the current price. The report provides specific strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
BHVN - Biohaven Ltd Latest SEC Filings
This article provides the latest SEC filing details for Biohaven Ltd (BHVN), including its stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The company has a market cap of $2.40 billion and shows significant institutional ownership, along with recent stock appreciation over various periods.
Biohaven Shares Drop 9.8% to $14.28
Biohaven's shares fell 9.8% to $14.28, following a downgrade from BofA to Underperform with a reduced price target of $11, citing a bearish view on the risk-reward ahead of Phase 3 data for their kv7 epilepsy drug. This contrasts with a Deutsche Bank upgrade to a $20 price target, maintaining a Buy rating, due to potential FDA reversals for their troriluzole drug in spinocerebellar ataxia. The company recently completed enrollment for its RISE3 study on opakalim for refractory focal epilepsy, with positive preliminary efficacy data, despite mixed analyst and market sentiment.
Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)?
Biohaven has advanced two key drug candidates, opakalim for refractory focal epilepsy and BHV-1300 for Graves' disease, into pivotal Phase 2/3 and Phase 3 trials, respectively. These milestones are critical for the biopharmaceutical company, which operates with no revenue, a high valuation, and significant cash burn. The market's current optimism, reflected in a recent share price rebound, suggests expectations for positive trial outcomes, though funding needs and valuation concerns remain significant factors for investors.
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Bank of America Securities downgraded Biohaven Ltd. to Underperform, lowering its price target to $11 from $12. The downgrade stems from concerns about Biohaven's lead epilepsy drug, Opakalim, which is expected to face significant competition from Xenon Pharmaceuticals' azetukalnar. Analysts believe Opakalim will struggle to achieve its projected peak sales without meaningful clinical differentiation, leading BofA to reduce its peak sales forecast for the drug.
Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment
Biohaven Ltd. (NYSE: BHVN) has completed enrollment in its pivotal Phase 2/3 RISE3 study for opakalim, a selective Kv7.2/7.3 activator, aimed at treating refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. The company reported promising data from an ongoing open-label extension, showing 54% of participants on opakalim 75 mg once daily achieved a 50% or greater reduction in seizure frequency with a favorable tolerability profile.
Biohaven completes enrollment in opakalim epilepsy trial
Biohaven Ltd. has completed enrollment in its pivotal Phase 2/3 trial, RISE3, for opakalim, a treatment for refractory focal epilepsy, with top-line results expected in the second half of 2026. The company's stock has surged 32% in the past six months, reflecting optimism about its epilepsy pipeline. Opakalim has demonstrated significant seizure reduction in an open-label extension study, with a good safety profile, while the company also faces analyst downgrades balanced by strong buy ratings due to other drug candidates for autoimmune diseases.
Biohaven completes enrollment in focal epilepsy drug trial
Biohaven Ltd. has completed enrollment in RISE3, a pivotal Phase 2/3 trial for opakalim, an investigational drug for refractory focal epilepsy. Top-line results for this study are anticipated in the second half of 2026. This development marks a significant step forward in the opakalim development program, which has already shown promising results in an ongoing open-label extension study.
Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12
BofA Securities has downgraded Biohaven Pharmaceuticals' rating from Neutral to Underperform. The firm also adjusted its price target for Biohaven, lowering it to $11 from $12. This revision reflects a more cautious outlook on the pharmaceutical company's future performance.
BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target
BofA Securities has downgraded Biohaven Pharmaceuticals' rating from Neutral to Underperform. The firm has also set a new price target of $11 for Biohaven's stock. This downgrade suggests a negative outlook on the company's future stock performance by BofA Securities.
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Biohaven Ltd. has announced the completion of enrollment in RISE3, a pivotal Phase 2/3 study for its selective Kv7.2/7.3 channel activator, opakalim, for refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. This study aims to provide a new treatment option that controls seizures effectively with a favorable tolerability profile, reducing central nervous system side effects often associated with current antiseizure medicines.
Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio
Biohaven Pharmaceuticals (BHVN) experienced a significant 9.8% stock decline on June 29, 2026, dropping to $14.28, reflecting market volatility and challenges for the clinical-stage biopharmaceutical company. The company has a low GF Score™ of 30/100 and a low profitability rank, indicating potential issues, despite some insider purchases. Investors are advised to exercise caution due to the absence of revenue generation and intrinsic value data.
Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA
Biohaven Pharmaceutical shares have dropped due to concerns over its Phase 3 trial results for taldefgrobep alfa in spinal muscular atrophy (SMA). BofA Securities downgraded Biohaven from Buy to Neutral and lowered its price target to $30, citing the trial's failure to meet its primary endpoint and questioning the drug's efficacy profile. The downgrade also considered the competitive landscape, where other treatments like Biogen's Spinraza and Roche's Evrysdi are already established.
BHVN Downgraded by B of A Securities -- Price Target Lowered to $11
Biohaven Ltd (BHVN) has been downgraded by B of A Securities to Underperform, with the price target lowered from $12.00 to $11.00. This reflects a cautious outlook on the clinical-stage biopharmaceutical company, which has a GF Score™ of 30/100, indicating potential challenges for long-term returns, particularly due to low profitability. Investors are advised to exercise caution given the downgrade and the company's GF Score™.
Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease
Biohaven Pharmaceutical Holding Company Ltd. has begun its Phase 3 clinical trial for BHV-1300, a treatment targeting Graves' Disease, with the first patient successfully dosed. This development marks a significant step for the company, which continues to advance its portfolio of therapies for neurological and neuropsychiatric conditions. Recent analyst adjustments to Biohaven's price targets reflect ongoing evaluations of their clinical pipeline.
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures showed gains on Monday morning, but several individual stocks were moving lower in pre-market trading. Biohaven shares tumbled after an analyst downgrade, while Larimar Therapeutics, Omeros Corp, Sadot Group Inc, and Freecast Inc also saw significant declines. Goodyear Tire & Rubber Co also fell following news of its CFO's resignation.
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Biohaven Ltd. has initiated a pivotal Phase 3 trial for BHV-1300, its first MoDE (extracellular protein degrader), targeting Graves' disease. This groundbreaking therapy aims to eliminate disease-driving antibodies at the root of the autoimmune condition, representing a significant shift from existing treatments that only manage symptoms. BHV-1300 has shown promising results in Phase 1b data, demonstrating rapid reduction of pathogenic autoantibodies and normalization of thyroid hormones with a favorable safety profile.
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Biohaven Ltd (BHVN), detailing its support, resistance levels, and various technical indicators. It shows that most indicators, including MACD, RSI, and moving averages, are signaling a "Buy" for BHVN. The analysis also explains general concepts of technical ratings and moving averages for investor reference.
ZH6 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Biohaven Ltd. (ZH6) stock, detailing analyst price targets with a max estimate of 44.02 EUR and a min of 7.92 EUR. It covers historical price performance, upcoming earnings dates, recent financial results including EPS and revenue, and notes that the company does not pay dividends. Key financial data and company details are presented, alongside disclaimers that the information is not investment advice.
Deutsche Bank Adjusts Biohaven Price Target to $20 From $15, Maintains Buy Rating
Deutsche Bank has increased its price target for Biohaven from $15 to $20 per share. The firm also reiterated its Buy rating on the stock, indicating continued confidence in the company's prospects.
Deutsche Bank Adjusts Biohaven Price Target to $20 From $15, Maintains Buy Rating
Deutsche Bank has increased its price target for Biohaven Pharmaceutical Holding Company Ltd. from $15 to $20 while reiterating a Buy rating. This adjustment suggests a positive outlook for the biopharmaceutical company despite potential regulatory hurdles. Biohaven's stock was recently trading at $15.61, indicating the new price target represents a significant potential upside.
Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials
Biohaven Ltd. (BHVN) announced it is advancing several immunology and oncology candidates, including BHV-1510, BHV-1530, BHV-1400, and BHV-1300, into pivotal trials, leading to a 22.2% stock price increase. The company's investment narrative is centered on its broad, early-stage pipeline justifying its valuation despite zero revenue and persistent losses. Investors are keenly watching clinical execution, trial initiations, and regulatory feedback due to the company's reliance on pipeline success and ongoing financing needs.
Biohaven Ltd. Actuals & Estimates (NYSE:BHVN)
This article provides an overview of Biohaven Ltd. (NYSE:BHVN), including its current stock price, market capitalization, and analyst forecasts. It details financial actuals and estimates, such as earnings and revenue, and answers frequently asked questions about the company's financial performance and stock dynamics. The article also mentions the company's next earnings report date and employee count.
Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials
Biohaven (BHVN) recently announced the advancement of several immunology and oncology candidates into pivotal clinical trials, including BHV-1510, BHV-1530, BHV-1400, and BHV-1300. This move reinforces the company's early-stage pipeline strategy and has led to a significant 22.2% increase in its stock price. Investors are now closely watching trial initiations, early readouts, and regulatory feedback, while also considering the company's financing needs and potential dilution due to zero revenue and persistent losses.
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials
Biohaven (BHVN) shares rose by 14.22% to $15.50 after investors increased their positions ahead of the initiation of two new clinical studies. The biopharmaceutical company plans to begin clinical trials for BHV-1510 and BHV-1530 by the end of the month, targeting advanced epithelial tumors and urothelial cancer, respectively. Biohaven also expects to start pivotal studies for IgAN and Graves’ disease treatments mid-year and significantly reduced its net losses in the first quarter.
Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares
Biohaven's stock rose 12.66% after announcing plans for pivotal clinical studies for cancer and autoimmune candidates. Despite recent short-term gains, the stock's 1-year return is down 6.2%, and its current P/B ratio of 15.8x is considered very expensive given the company's unprofitability and lack of near-term profitability forecasts. This suggests the market is pricing in future pipeline success, highlighting potential overvaluation and execution risks if clinical results disappoint.
Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares
Biohaven's stock rose significantly after announcing plans for pivotal clinical studies for several cancer and autoimmune candidates. Despite recent short-term gains, the company's 1-year total shareholder return declined, and it trades at a high price-to-book multiple of 15.8x while being unprofitable and not forecast to achieve profitability in the next three years. This elevated valuation is attributed to market expectations for its pipeline and revenue growth rather than current financials, with potential risks if clinical results disappoint.
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Biohaven Ltd (BHVN), detailing future EPS and revenue growth estimates. Based on 19 analysts, the company has a "Buy" rating with a target price of USD 22.188, representing a 62.90% upside. Key figures include an expected revenue of 394.17K for the next quarter and an EPS forecast of USD -0.72.
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Biohaven Ltd (BHVN), focusing on key metrics like P/E, P/B, P/S, and P/CF ratios. As of the report, relevant data for these valuation metrics have not been disclosed by the company. The analysis is part of a broader company overview provided by TradingKey, which also includes discussions on financial health, earnings forecasts, price momentum, and institutional confidence.
Biohaven Ltd (BHVN) Institutional Confidence
This article from TradingKey focuses on the institutional confidence in Biohaven Ltd (BHVN), detailing key institutional shareholders and their recent activity. It lists top shareholders like Janus Henderson Investors and Suvretta Capital Management, LLC, along with the shares held and percentage change in their holdings. The report indicates a significant increase in institutional interest in BHVN.
Biohaven Ltd (BHVN) Financial Health: Profitability & Balance Sheet Analysis
This article from TradingKey provides a financial health analysis of Biohaven Ltd (BHVN), focusing on its profitability and balance sheet. However, it notes that relevant data for categories such as Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company. The overview includes the stock's current price, market cap, and a general score.
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE
This page provides live quotes and charts for Biohaven Ltd. (BHVN) stock on the NYSE, showing its current price and daily performance. It highlights the stock's performance over various periods and mentions that there are no current analyst ratings or earnings information available. The page includes promotional content for trading bootcamps and algorithmic trade alerts.
Biohaven Ltd (BHVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article for Biohaven Ltd (BHVN) states that relevant data regarding its revenue breakdown by business segments and regions has not yet been disclosed by the company. This information is currently unavailable, preventing a detailed analysis of the company's revenue streams.
Biohaven Ltd (BHVN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Biohaven Ltd (BHVN), listing major individual and institutional holders, their proportional ownership, and recent changes in their holdings. It also categorizes shareholders by type (e.g., Investment Advisor/Hedge Fund), provides historical institutional shareholding data, and lists related ETFs that include BHVN.
Biohaven Ltd (BHVN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Biohaven Ltd's (BHVN) dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years and reports no data available for past stock splits. The page also presents current stock information including the market price, daily change, and market capitalization.
Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates
Biohaven Ltd. (BHVN) saw its stock climb 12.66% to $13.62, driven by investor anticipation of upcoming clinical studies for its cancer treatment candidates. The biopharmaceutical company is set to initiate pivotal trials for BHV-1510 for epithelial tumors and BHV-1530 for urothelial cancer by the end of the month, with additional studies for IgAN and Graves' disease planned for mid-year. In Q1, Biohaven reduced its net losses by 41%, despite not yet generating revenue.
Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates
Biohaven Ltd. (NYSE:BHVN) saw its stock climb by 12.66% ahead of the initiation of two pivotal studies for its endometrial and urothelial cancer treatment candidates. The biopharmaceutical company is also planning to initiate pivotal studies for treatments related to IgAN and Graves’ disease. In the first quarter of the year, Biohaven managed to reduce its net losses by 41 percent.
(BHVN) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily analyzes Biohaven Ltd. (NASDAQ: BHVN) using AI-driven algorithmic entry frameworks. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying a mid-channel oscillation pattern. The analysis presents specific institutional trading strategies, including long, breakout, and short setups, along with multi-timeframe signal analysis and risk-reward ratios.
How Biohaven’s Precision Immunology Pipeline Updates Will Impact Biohaven (BHVN) Investors
Biohaven recently announced first-in-human dosing for BHV-8100 and early clinical data for BHV-1300 and BHV-1400, highlighting its strategy to combine brain energy metabolism with precision immunology. While these updates add scientific credibility, the company faces significant investment challenges, including zero revenue, substantial losses, and a short cash runway, raising concerns about potential dilution. Investor sentiment is mixed, with a wide range of fair value estimates, underscoring the differing views on the company's platform promise versus its financial risks and execution.
Biohaven | DEF 14A: Definitive information statements
This document, a DEF 14A filing from Biohaven, contains definitive information statements. These filings are crucial for shareholders, providing detailed information ahead of important corporate events such as annual meetings or merger proposals.
How Biohaven’s Precision Immunology Pipeline Updates Will Impact Biohaven (BHVN) Investors
Biohaven recently announced first-in-human dosing for BHV-8100 and promising early clinical data for its degrader candidates, BHV-1300 and BHV-1400. These advancements aim to build a differentiated portfolio connecting brain energy metabolism with precision immunology, potentially influencing the company's investment narrative. Despite scientific credibility from these updates, Biohaven faces significant financial hurdles, including a rich valuation, ongoing losses, and a short cash runway, alongside diverse investor expectations regarding its stock's fair value.
A Look At Biohaven (BHVN) Valuation After Fresh Pipeline Updates For BHV 8100 BHV 1300 And BHV 1400
Biohaven (BHVN) has seen renewed investor interest following recent R&D updates for its pipeline candidates BHV-8100, BHV-1300, and BHV-1400. Despite a choppy share price and a significant premium based on its Price to Book multiple of 12.9x (compared to an industry average of 2.3x), the company remains loss-making with no revenue. Investors are weighing the potential of its clinical-stage pipeline against risks like limited cash runway and continued net losses.
Biohaven Pharmaceutical Holding Company Ltd (BHVN) News, Articles, Events & Latest Updates
This page provides the latest news and updates for Biohaven Pharmaceutical Holding Company Ltd (BHVN), including stock performance, financial data, and recent press releases. Key updates include the first-in-human dosing of an oral PKM2 modulator, positive clinical data for extracellular protein degraders, and new epilepsy data from a Kv7.2/7.3 activator. The article also mentions recent analyst ratings and the company's first-quarter 2026 financial results.
Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%?
Biohaven Ltd. (NYSE:BHVN) has initiated first-in-human dosing for BHV-8100, a potential breakthrough for metabolic and immune dysfunction, and reported compelling results for BHV-1300 and BHV-1400 in various diseases. Despite a lowered price target by RBC Capital, Biohaven continues to advance its programs in immunology, neuroscience, and oncology. The article also promotes investment in AI stocks, suggesting they might offer higher returns within a shorter timeframe than BHVN, and highlights a specific "cheapest AI stock" with significant upside potential.
Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%?
Biohaven Ltd. (NYSE:BHVN) has initiated first-in-human dosing for BHV-8100, its oral, brain-penetrant pyruvate kinase M2 isoform modulator, which is considered a potential breakthrough for metabolic and immune dysfunction disorders. The company also reported compelling results for BHV-1300 in Graves’ Disease and BHV-1400 in IgA nephropathy, with these programs progressing towards pivotal trials. Despite a recent price target reduction by RBC Capital, BHVN maintains an Outperform rating, though the article suggests that certain AI stocks may offer greater upside and less risk.
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX)
Analyst ratings indicate a bullish sentiment for Biohaven Ltd. (BHVN) and Abivax SA Sponsored ADR (ABVX) within the Healthcare sector. RBC Capital maintained a Buy rating for Biohaven with a $22.00 target, while LifeSci Capital reiterated a Buy rating for Abivax with a $170.00 target. Both companies show significant upside potential according to the analyst consensus.
Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?
Biohaven recently announced pipeline advancements, including first-in-human dosing of BHV-8100 (a PKM2 modulator) and positive clinical data for autoimmune candidates BHV-1300 and BHV-1400. While these developments reinforce Biohaven's broad pipeline and focus on metabolically targeted neurology and precision immunology, they do not immediately alter near-term investment catalysts. The company faces significant losses and dilution risks, but the long-range narrative is strengthened.
Is Biohaven’s PKM2 and Autoimmune Pipeline Progress Altering The Investment Case For Biohaven (BHVN)?
Biohaven recently announced pipeline advancements, including first-in-human dosing of BHV-8100 and positive clinical data for autoimmune candidates BHV-1300 and BHV-1400. While these updates broaden Biohaven's potential beyond a single asset, the company continues to face significant losses and a limited cash runway. The investment narrative remains focused on its high-risk pipeline, with analysts offering widely varying fair value estimates due to the company's financial situation versus its potential.
Biohaven (NYSE:BHVN) - analisi del titolo
Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on treatments in immunology, neurosciences, and oncology, with its stock currently trading at US$10.80. The company is actively conducting various clinical trials, including those for metabolic and immune disorders (BHV-8100), Graves' Disease and IgA Nephropathy (BHV-1300 and BHV-1400), epilepsy (Opakalim), and obesity (Taldefgrobep Alfa). Despite a projected revenue growth of 67.24% annually, Biohaven faces financial risks such as unprofitability, accumulated deficit, and a volatile share price.
Biohaven begins first human trial of brain-penetrant drug BHV-8100
Biohaven Ltd. has initiated the first human trial for its oral drug BHV-8100, designed to target the PKM2 enzyme for metabolic and immune disorders affecting the central nervous system. Preliminary Phase 1 data indicates the drug reaches therapeutic levels with once-daily dosing. BHV-8100 showed promising results in preclinical models, including improved glucose utilization in human donor brains and metabolic restoration in Alzheimer's and multiple sclerosis models.
